Mode of action of lithium: some biological considerations.
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001714:Bipolar Disorder / Q000378:metabolism; D001921:Brain / Q000378:metabolism; D002352:Carrier Proteins / Q000378:metabolism; D000242:Cyclic AMP / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism / Q000494:pharmacology; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D007473:Ion Channels / Q000378:metabolism; D008094:Lithium / Q000378:metabolism / Q000494:pharmacology*; D009638:Norepinephrine / Q000378:metabolism; D011188:Potassium / Q000378:metabolism; D051381:Rats; D011954:Receptors, Dopamine / Q000187:drug effects; D012964:Sodium / Q000378:metabolism; D013570:Synaptic Membranes / Q000378:metabolism
D002352:Carrier Proteins; D007473:Ion Channels; D011954:Receptors, Dopamine; D008094:Lithium; D012964:Sodium; D000242:Cyclic AMP; D006220:Haloperidol; D001058:Apomorphine; D011188:Potassium; D004298:Dopamine; D009638:Norepinephrine